Zalypsis

DB12454InvestigationalSmall molecule

Zalypsis has been used in trials studying the treatment of Lymphoma, Solid Tumors, Ewing's Sarcoma, Endometrial Cancer, and Uterine Cervical Cancer, among others.

Mechanism: Pharmacologically active on DNA
Curator reviewed
Formula / weight: C₃₇H₃₈F₃N₃O₈ · 709.719 g/mol (avg)
Code names: PM-00104

Resolves to

Compound

UNIIC21EZR41AYCAS308359-57-1PubChem16061448

Structure

InChIKeyVPAHZSUNBOYNQY-DLVGLDQCSA-NSMILES

COC1=C(O)C2=C(C[C@H]3[C@H](O)N4[C@@H](CC5=C([C@@H]4CNC(=O)\C=C\C4=CC=CC(=C4)C(F)(F)F)C4=C(OCO4)C(C)=C5OC(C)=O)[C@@H]2N3C)C=C1C

What you can answer from here — as of October 11, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Zalypsis, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account